Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).

Masatoshi Kudo,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Ellen B Gurary,Abby B. Siegel,Lokesh Jain,Ann-Lii Cheng,Andrew X. Zhu

Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC).

2020

518Background: Pembro received accelerated approval in pts with advanced HCC in the second-line setting based on results of the KEYNOTE-224 trial. Results of a 2 y follow-up analysis of the efficac...

Keywords:

Hepatocellular carcinoma
Pembrolizumab
Phases of clinical research
Internal medicine
Medicine
Oncology
Pathology
in patient
accelerated approval

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations